- Home
- CLB vs STOK Comparison
CLB vs STOK Comparison
Compare CLB & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLB
- STOK
- Stock Information
- Founded
- CLB 1936
- STOK 2014
- Country
- CLB United States
- STOK United States
- Employees
- CLB N/A
- STOK N/A
- Industry
- CLB
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- CLB
- STOK Health Care
- Exchange
- CLB Nasdaq
- STOK Nasdaq
- Market Cap
- CLB 717.9M
- STOK 517.0M
- IPO Year
- CLB 1995
- STOK 2019
- Fundamental
- Price
- CLB $11.08
- STOK $9.05
- Analyst Decision
- CLB Hold
- STOK Strong Buy
- Analyst Count
- CLB 4
- STOK 5
- Target Price
- CLB $15.75
- STOK $27.50
- AVG Volume (30 Days)
- CLB 607.4K
- STOK 788.4K
- Earning Date
- CLB 04-23-2025
- STOK 05-20-2025
- Dividend Yield
- CLB 0.35%
- STOK N/A
- EPS Growth
- CLB N/A
- STOK N/A
- EPS
- CLB 0.59
- STOK N/A
- Revenue
- CLB $517,796,000.00
- STOK $36,555,000.00
- Revenue This Year
- CLB $3.63
- STOK $27.80
- Revenue Next Year
- CLB $3.39
- STOK $9.53
- P/E Ratio
- CLB $19.11
- STOK N/A
- Revenue Growth
- CLB 1.32
- STOK 316.34
- 52 Week Low
- CLB $10.14
- STOK $5.35
- 52 Week High
- CLB $25.13
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- CLB 37.60
- STOK 54.73
- Support Level
- CLB $11.04
- STOK $8.30
- Resistance Level
- CLB $12.45
- STOK $10.12
- Average True Range (ATR)
- CLB 0.72
- STOK 0.66
- MACD
- CLB 0.07
- STOK -0.03
- Stochastic Oscillator
- CLB 1.85
- STOK 59.47
About CLB Core Laboratories Inc.
Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.